A5055330253- Bone health and osteoporosis research
- Bone health and treatments
- Bone Metabolism and Diseases
- Hip and Femur Fractures
- Bone and Joint Diseases
- Bone fractures and treatments
- Estrogen and related hormone effects
- Vitamin D Research Studies
- Osteoarthritis Treatment and Mechanisms
- Parathyroid Disorders and Treatments
- Orthopaedic implants and arthroplasty
- Nutrition and Health in Aging
- Menopause: Health Impacts and Treatments
- Spine and Intervertebral Disc Pathology
- Dental Implant Techniques and Outcomes
- Spinal Fractures and Fixation Techniques
- Musculoskeletal pain and rehabilitation
- Pelvic and Acetabular Injuries
- Hip disorders and treatments
- Renal function and acid-base balance
- Pharmacological Effects and Toxicity Studies
- Tendon Structure and Treatment
- Medical Imaging Techniques and Applications
- Total Knee Arthroplasty Outcomes
- Knee injuries and reconstruction techniques
University of Bern
2016-2025
University Hospital of Bern
2016-2025
Danaher (United States)
2012
San Salvatore Hospital
2012
Industrial Development Agency JSC (Poland)
2012
KU Leuven
2010
University of Sheffield
2010
University of Pittsburgh
2010
Université Claude Bernard Lyon 1
2010
University of California, San Francisco
2010
Abstract Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and risk, the Health Outcomes Reduced Incidence Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 who received core study were randomized additional (Z6, n = 616) or placebo (Z3P3, 617)....
Abstract. Introduction. Vitamin D is essential for calcium metabolism as well fracture prevention, and a recent review suggested that the optimal serum 25(OH)D lies in region of 50–80 nmol L −1 (20–32 ng mL ). A high prevalence inadequacy has been reported many studies but amongst women with osteoporosis different regions world not characterized. Setting subjects. multinational study 18 countries at various latitudes (range 64N–38S) was conducted 2004 2005 to determine average levels vitamin...
Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis limited. We studied effect zoledronic acid fracture risk among with osteoporosis.
The FREEDOM study and its Extension provide long-term information about the effects of denosumab for treatment postmenopausal osteoporosis. Treatment up to 8 years was associated with persistent reduction bone turnover, continued increases in mineral density, low fracture incidence, a favorable benefit/risk profile.This aims report results through year 5 study, representing women osteoporosis.Women who completed 3-year were eligible enter 7-year open-label which all participants are...
Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap osteoporosis and paucity bone-forming agents for men, new treatments are needed. To evaluate safety efficacy romosozumab with osteoporosis. Phase III randomized BRIDGE study (placebo-controlled double-blind evaluating treating osteoporosis; ClinicalTrials.gov identifier, NCT02186171) 12 months. Thirty-one centers Europe, Latin America, Japan, North America. Men 55 90 a...
ABSTRACT While bisphosphonates reduce fracture risk over 3 to 5 years, the optimal duration of treatment is uncertain. In a randomized extension study (E1) Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly−Pivotal Fracture Trial (HORIZON−PFT), zoledronic acid (ZOL) mg annually for 6 years showed maintenance bone mineral density (BMD), decrease in morphometric vertebral fractures, modest reduction turnover markers (BTMs) compared discontinuation after years. To...
The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk fractures postmenopausal women with osteoporosis.We evaluated effect on incidence new vertebral and hip subgroups at higher for these fractures.FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial.Postmenopausal (N = 7808) osteoporosis were enrolled 213 study sites worldwide.Subjects received s.c. (60 mg) or placebo months...
Abstract We report on a female who is compound heterozygote for two new point mutations in the CYP19 gene. The allele inherited from her mother presented base pair deletion (C) occurring at P408 (CCC, exon 9), causing frameshift that results nonsense codon 111 bp (37 aa) further down father showed mutation G->A splicing (canonical GT to mutational AT) between and intron 3. This ignores splice site stop 3 downstream occurs. Aromatase deficiency was already suspected because of marked...
ABSTRACT Romosozumab is a bone-forming agent with dual effect of increasing bone formation and decreasing resorption. In FRActure study in postmenopausal woMen ostEoporosis (FRAME), women osteoporosis received romosozumab 210 mg s.c. or placebo once monthly for 12 months, followed by denosumab 60 every 6 months both groups months. One year increased spine hip BMD 13% 7%, respectively, reduced vertebral clinical fractures persistent fracture risk reduction upon transition to over 24 Here, we...
Abstract To assess bone mineral density (BMD) in idiopathic calcium nephrolithiasis, dual-energy x-ray absorptiometry was performed at lumbar spine, upper femur (femoral neck, Ward's triangle, and total area), distal tibial diaphysis, epiphysis 110 male stone formers (ICSF); 49 with 61 without hypercalciuria on free-choice diet). Results were compared those obtained 234 healthy controls, using (1) noncorrected BMD, (2) BMD corrected for age, height, BMI, (3) a skeletal score based tercile...
With lengthening (eccentric) muscle contractions, the magnitude of locomotor-muscle mass and strength increase has been demonstrated to be greater compared with shortening (concentric) contractions. In healthy subjects, energy demand heart rate responses eccentric exercise are small relative amount force produced. Thus, may an attractive alternative resistance for patients limited cardiovascular tolerance.We tested tolerance in 13 coronary (ages 40-66) preserved and/or mild reduced left...